Infertility Clinical Trial
Official title:
Activating Blood, Dredging Liver and Nourishing Kidney Sequential Treatment for Endometriosis Associated Infertility - a Randomized Double-blind Placebo Controlled Study
Endometriosis is a common, chronic disease. 30% to 50% of women with endometriosis are infertile. There is moderate quality evidence that laparoscopic surgery to treat mild and moderate endometriosis increases live birth or ongoing pregnancy rates. There was no evidence of benefit for post-surgical hormonal suppression of endometriosis compared to surgery alone for the outcomes of pregnancy rates. Past studies have confirmed that Chinese herbal medicine can inhibit post-surgical endometriosis recurrence, increase pregnancy rate.This study evaluates the efficacy and safety of Traditional Chinese Medicine Sequential Treatment of endometriosis-associated infertility. The study objective is to confirm that clinical pregnancy rate of patients with endometriosis-associated infertility post-conservative surgery accepting Chinese medicine activating blood, dredging liver and nourishing kidney sequential treatment is higher than expectant treatment.
This study is a randomized, double-blind, placebo-controlled, multicenter, prospective
clinical study, conducted in China (six research centers).
204 cases of patients with endometriosis-associated infertility confined with Syndrome of qi
stagnation blood stasis pattern in TCM after conservative surgery will be recruited.
Patients will be randomly divided into two groups: experimental group (TCM Sequential
Treatment) and control group (placebo). All the patients are treated for six menstrual
cycles, taking pre-ovulation decoction before ovulation and post-ovulation decoction after
ovulation. Pre-ovulation decoction of experimental group is HuoXueXiaoYi decoction, and
post-ovulation decoction is BuShenZhuYun decoction. The drug of control group is placebo.
Each menstrual cycle, patient is monitored of antral follicle count (AFC), ovulation,
endometrial thickness, and endometrial blood flow by ultrasonography, and need fill TCM
syndrome rating scale, pictorial blood loss assessment chart (PBAC), and the visual analogue
scale(VAS).The 1st, 3rd, 6th menstrual cycle after surgery, the level of serum female
hormone (FSH, LH, E2) are detected in menstrual period of 2 to 5 days, and female hormone
(E2, P) in the middle of the corpus luteum 6-9 days.
Patient must be security check (blood routine, urine routine, liver and kidney function,
electrocardiogram) before and after drug treatment. Such as patients find pregnancy during
medication, adopt the security check in finding pregnancy 7 days.
Patients after amenorrhea need to be confirmed pregnancy by serum β-HCG detection. According
to the level of serum HCG, E2 and P and clinical symptoms, corresponding tocolytic treatment
will be given. At 6~8 weeks of pregnancy, patient need to be confirmed the clinical
pregnancy by ultrasonography. If confirmed the clinical pregnancy (at least having one heart
throb in intrauterine gestational sac), patient need to be confirmed ongoing pregnancy by
ultrasonography at the 12~14 weeks of pregnancy.
In the process of the entire study, adverse events will be closely observed, and the
frequency and severity of adverse events will be recorded.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A |